Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Wolf, B. W.; Garleb, K. A.; Ataya, D. G.; Casas, I. A. (2011)
Publisher: Microbial Ecology in Health and Disease
Journal: Microbial Ecology in Health and Disease
Languages: English
Types: Article

Classified by OpenAIRE into

mesheuropmc: food and beverages
Thirty healthy, male subjects (age I8 to 75 yrs) were used in a two-group, double-blinded, parallel design to evaluate the safety and tolerance of a potential probiotic organism, Lactobacillus reuteri. Subjects ( 15/treatment) consumed two gelatin capsules daily for 21 d that contained either a freeze dried L. reuteri preparation in a cryoprotectant, or a placebo (cryoprotectant). The concentration of L. reuteri was such that subjects consumed 1 x 1011 CFU per day. The study was 28 d in length with daily documentation of the presence of gastrointestinal symptoms (nausea, diarrhoea, cramping, distention, flatulence, vomiting, constipation, burping and reflux). In addition, serum chemistries, haematology, urinalysis, urinary indican excretion, and faecal microbiota (L. reuteri and total Lactobacillus spp. enumeration) were measured weekly (day 0, 7, 14, 21 and 28). A physical exam was given on day 0. 21, and 28. An additional faecal sample was obtained on day 77 for microbial enumeration. Subjects could consume their regular diets; however, alcohol was not allowed. Physical exam and urinalysis parameters were not clinically direrent between treatments. Supplemental L. reuteri reduced (P<0.05) urinary indican excretion at day 7, but had no effect (P>0.05) on subsequent urine collections. Although significant differences were observed for a few of the serum chemistry and haematology variables, all of the d u e s remained within the expected normal range for healthy adult males. Subjects consuming supplemental L. reuteri ad increased (P<0.05) between treatments; however, the ratio of L. reuteri: total Lactobacillus spp. increased (P<0.05) for subjects consuming supplemental L. reuteri. Incidence of subjective tolerance factors was infrequent and similar for both treatments. In conclusion, supplemental L. reuteri may be fed at 1 x 1011 CFU/day without any clinically significant safety or tolerance problems. Intake of L. reuteri (1 x 1011 CFU/day) results in colonisation (as measured by faecal level) within 7 d of consumption and is maintained for at least 7 d post consumption; however, colonisation is lost within 2 mths of washout.Keywords: Lactobacillus reuteri; safety and tolerance; faecal lactobacilli level.

Share - Bookmark

Cite this article

Collected from